Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.
Investing.com -- Tectonic Therapeutic (NASDAQ:TECX) stock surged 18% after the company announced positive topline results from its Phase 1b Part B clinical trial for TX45 in patients with Group 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback